Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ (3,107)	$ (14,852)	$ (9,159)	$ (30,248)
General and administrative	(1,780)	(1,833)	(5,867)	(5,789)
Total operating expenses	(4,887)	(16,685)	(15,026)	(36,037)
Operating loss	(4,887)	(16,685)	(15,026)	(36,037)
Interest expense, net	(590)	(300)	(1,648)	(1,023)
Adjustments to fair value of derivatives	(433)	13,199	(1,226)	11,361
Other (expense) / income, net	(48)	70	(77)	161
Total other (expense) / income	(1,071)	12,969	(2,951)	10,499
Loss before income taxes	(5,958)	(3,716)	(17,977)	(25,538)
Income tax expense	(136)	(161)	(215)	(471)
Net loss	$ (6,094)	$ (3,877)	$ (18,192)	$ (26,009)
Net loss per share - basic	$ (0.3)	$ (0.3)	$ (1.05)	$ (2.02)
Net loss per share - diluted	$ (0.3)	$ (0.3)	$ (1.05)	$ (2.02)
Weighted average ordinary shares outstanding - basic	20,044,270	13,039,437	17,352,918	12,888,869
Weighted average ordinary shares outstanding - diluted	20,044,270	13,039,437	17,352,918	12,888,869
Other comprehensive income:
Net loss	$ (6,094)	$ (3,877)	$ (18,192)	$ (26,009)
Unrealized gain on marketable securities	3	29	1	353
Comprehensive loss	$ (6,091)	$ (3,848)	$ (18,191)	$ (25,656)